Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study

Documenti analoghi

• Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach
  di: Rune Viig Overgaard, et al.
  Pubblicazione: (2026)
• Real‐World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non‐Diabetic Adults
  di: Mai Katsura, et al.
  Pubblicazione: (2026)
• Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT Trials
  di: Dirk Müller‐Wieland, et al.
  Pubblicazione: (2026)
• Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III , Active‐Controlled Study
  di: Unnikrishnan Ambika Gopalakrishnan, et al.
  Pubblicazione: (2026)
• Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study
  di: Assaf Issachar, et al.
  Pubblicazione: (2026)